Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025Frontiers in MedicineOpen Access

Pembrolizumab in the treatment of non-small cell lung cancer—experiences from clinical practice

View Full Paper
Ask AI
Bookmark
Share

Authors

LLLora Novaković LackovićMTMarija TomićMNMarko Novakovic

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows lower response rates and improved survival in NSCLC patients treated with pembrolizumab, indicating clinical benefit despite challenges.

Key Points

  • The objective response rate for pembrolizumab was 72.2%, lower than the 85.7% seen in clinical trials.
  • Patients had a median overall survival of 36 months, showing significant benefits despite advanced disease.
  • This retrospective analysis included 46 patients treated with pembrolizumab from 2018 to 2022, highlighting real-world efficacy.
  • Results suggest that while treatment outcomes vary, pembrolizumab remains beneficial for NSCLC management.

Cite This Study

Lacković et al. (2025) studied this question.

synapsesocial.com/papers/68c239a3b210217d6477c83dhttps://doi.org/10.3389/fmed.2025.1635626
View Full Paper
Ask AI
Bookmark
Share